/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | JAZZJazz Pharmaceuticals |
|---|---|
| Last close | $236.97 |
| Change % | -2.81% |
| Market cap | $14.9B |
| P/E | — |
| Revenue | $4.3B |
| Rev growth (YoY) | 4.9% |
| Net income | $-356148000 |
| Net margin | -8.3% |
| EPS (diluted) | $-5.84 |
| Piotroski F-Score | 5 |
| Altman Z-Score | — |
| Beneish M-Score | — |
| Next earnings | 07-30 → 08-09 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Green = best in the row among the compared names. Educational only — not investment advice.